World Health Organization

Marking a Milestone: Q&A on the First World Cervical Cancer Elimination Day

Is it really possible to eliminate cervical cancer—not just reduce it or manage it, but wipe it off the map for good? The World Health Organization (WHO) says yes, and has set ambitious global targets to get there by 2030.

The WHO’s 90‑70‑90 cervical cancer elimination strategy calls for:

  • 90% of girls vaccinated against HPV by age 15
  • 70% of women screened by age 35 and again at 45
  • 90% of those diagnosed receiving timely treatment

But meeting this deadline will take more than aspiration—it will take collective action. And today is a major step forward.

November 17, 2025, is the first-ever World Cervical Cancer Elimination Day, designated earlier this year by the World Health Assembly. Think of it like World AIDS Day or World Polio Day—global observances that didn’t just raise awareness, but helped spark the vaccines, screenings, and policies that pushed those diseases to the brink of eradication.

Cervivor, Inc. Founder and Chief Visionary Tamika Felder and Nigeria’s First Lady and healthcare pioneer, Dr. Zainab Shinkafi-Bagudu, were among the leaders who advocated for the day’s creation, including co-authoring a global call to action via the World Economic Forum to support it and elevate its importance on the world stage.

“I started Cervivor 20 years ago to support those affected by cervical cancer, hoping one day it wouldn’t be needed,” Tamika reflected at the time. “But too many communities are still suffering and dying from this preventable disease. A global day of recognition sends a powerful message: Awareness isn’t enough—the time for education, action, and elimination is now.”

Tamika delivers her annual “State of Cervical Cancer” address at the 2025 Cervical Cancer Summit—rallying survivors, advocates, and health leaders toward a future free from cervical cancer.

Below, we bring you an exclusive Q&A with Tamika and Dr. Bagudu, who is also Founder and CEO of the Medicaid Cancer Foundation and President-elect of the Union for International Cancer Control (UICC), answering the same questions from Maryland, USA, and Kebbi State, Nigeria, respectively. Their voices—one from the frontlines of African health equity and the other from the heart of patient advocacy—remind us: Elimination isn’t a solo act. It’s a chorus.

Q: Why does World Cervical Cancer Elimination Day matter?

Tamika: As a cervical cancer survivor, this day feels deeply personal. It represents something I once couldn’t imagine: hope for a world where no one else has to hear the words “you have cervical cancer.” When the World Health Organization declared that eliminating cervical cancer is within reach, it turned our fight from awareness into action.

For survivors, this first official World Cervical Cancer Elimination Day is a milestone that honors every story, every loss, and every victory along the way. It reminds us that our voices matter and that lived experience can guide smarter policies, stronger outreach, and more compassionate care.

Dr. Bagudu: World Cervical Cancer Elimination Day is symbolic—a rallying point for action. The WHO’s declaration that elimination is within reach shows this is an achievable reality if we commit to the right strategies.

  • Globally, it unites countries around a common goal: HPV vaccination, wider screening, and timely treatment. As President-elect of the UICC, I see this observance as a vital tool to keep cervical cancer high on the agenda, especially for low- and middle-income countries.
  • Nationally in Nigeria, it validates years of advocacy by First Ladies Against Cancer (FLAC), which I co-founded. The FLAC Screening Clinic in Kebbi is one example of how global commitments can translate into local action.
  • Personally, it is deeply meaningful. As a physician, mother, and advocate, I have seen both the devastation of late diagnosis and the hope that comes with early screening or HPV vaccination.

Ultimately, this day transforms aspiration into accountability. It tells the world: We can, and we must, eliminate this disease in our lifetime.

Dr. Bagudu, presenting a diagram of the female reproductive system to women in a rural community in Kuje, Abuja, aims to empower people in her country—and around the world—with life-saving information on cervical cancer prevention and the importance of early screening.

Q: How can a global day like this drive real change?

Tamika: We’ve seen the power of global observances before. Days like World AIDS Day and World Polio Day didn’t just raise awareness; they mobilized action, funding, and accountability. World Cervical Cancer Elimination Day can do the same.

In the United States, it can shine a light on the inequities that persist in prevention and care while inspiring innovation and collaboration. When survivors, clinicians, policymakers, and advocates unite around a shared message, we can accelerate progress toward eliminating this preventable cancer.

Dr. Bagudu: Nigeria has made important strides. The government’s rollout of the HPV vaccination program is a landmark step, protecting millions of young girls. Screening services are also expanding, with initiatives like the FLAC Screening Clinic in Kebbi showing how early detection can be brought closer to communities.

Civil society has been central. Through First Ladies Against Cancer (FLAC), we’ve sustained awareness campaigns, mobilized resources, and ensured continuity of programs. Partnerships with groups like Roche and the Clinton Health Access Initiative have strengthened diagnostics and treatment pathways. And of course, the Medicaid Cancer Foundation is at the heart of it all.

Still, challenges remain. Many rural women face barriers of distance, cost, and stigma. Shortages of trained health workers delay follow-up and treatment. And while HPV vaccines are now part of the national program, consistent supply and uptake across all states will require sustained political will and funding.

For me, this progress proves that change is possible when government, civil society, and partners work together. But it also reminds us that elimination will not happen automatically—it demands accountability, innovation, and persistence.

Q: Why is cervical cancer elimination especially urgent in low-resource regions?

Tamika: The U.S. has the knowledge and tools to prevent nearly all cervical cancers, yet persistent inequities mean prevention isn’t reaching everyone. Communities of color, people in rural areas, immigrants, people without reliable insurance, and those with language or transportation barriers face higher risks and lower access to vaccination, screening, and timely treatment. As a survivor, I know how much access, awareness, and advocacy can determine outcomes.

Elimination in the U.S. must start with equity. That means expanding vaccination access in schools and clinics, funding community-led education, and supporting policies that make screening and treatment affordable and available for everyone. Until every community is reached, we have not truly achieved elimination.

At the recent Patient Advocacy Retreat for Communities of Color in New Orleans, Tamika Felder (far right) leads survivors and advocates in grassroots outreach—bringing life-saving cervical cancer education directly into underserved communities.

Dr. Bagudu: Cervical cancer is a stark example of global health inequity. While it is increasingly rare in high-income countries, including the U.S., it remains a leading cause of cancer deaths in Africa, where women are more likely to be diagnosed late, less likely to access treatment, and more likely to die from a preventable disease.

In Nigeria, the challenges are clear:

  • Access is uneven; urban women may find screening in tertiary hospitals, but rural women face long distances, high costs, and limited awareness.
  • Stigma and cultural barriers discourage care until symptoms are advanced.
  • Health system gaps include shortages of trained personnel, diagnostic tools, and reliable vaccine supply chains.

Yet there are real opportunities. The national HPV vaccination rollout can protect millions of girls. Screening is expanding through models like the FLAC Clinic in Kebbi, which shows how state leadership can drive change. Through the Medicaid Cancer Foundation and First Ladies Against Cancer, we’ve raised awareness, supported patients, and built partnerships that strengthen care.

As President-elect of UICC, I can amplify Africa’s voice globally, while at the grassroots, we continue training health workers and engaging communities. Cervical cancer elimination is urgent because every delay costs lives—but with political will, investment, and collaboration, it is achievable, and African women must not be left behind.

Q: What progress have you seen—and what gaps remain?

Dr. Bagudu: We are at a turning point. In Nigeria and across Africa, real progress has been made against cervical cancer.

The national HPV vaccination rollout is a landmark milestone, protecting millions of girls. Screening services are expanding, with clinics like the FLAC Screening Clinic in Kebbi, and awareness campaigns are beginning to shift cultural attitudes. Treatment capacity is also improving, with more cancer centers equipped for radiotherapy and chemotherapy, while education efforts keep cancer high on the agenda.

Still, the gaps are stark. Too many women are diagnosed late, rural and low-income communities face barriers of distance, cost, and stigma, and health systems struggle with workforce shortages, supply chain issues, and limited palliative care.

This is why innovation is critical. Self-collection for HPV testing, digital health tools, mobile outreach, and task-shifting to community health workers can expand access dramatically.

The Medicaid Cancer Foundation (MCF) is helping bridge these gaps by running awareness campaigns, supporting screening in urban and rural areas, providing financial and psychosocial support through our PACE program, and advocating for sustainable funding and best practices. Beyond Nigeria, we collaborate with regional and global partners to strengthen advocacy and ensure Africa’s challenges are reflected in international strategies.

In short, progress is real, but urgency remains. With innovation, collaboration, and sustained commitment, we can close the gaps and move decisively toward eliminating cervical cancer across the continent.

Dr. Bagudu speaks at the just-concluded Medicaid Cancer Foundation disbursement of roughly $70,000 to cancer patients in Abuja, highlighting the Foundation’s commitment to patient-centered care and financial support.

Tamika: From where I stand, what’s changing most is momentum. More people are learning that HPV causes cervical cancer, vaccination rates are improving in some regions, and new technologies like HPV self-collection are showing incredible promise. Survivors are stepping into leadership roles and helping shape the national conversation about prevention and equity.

But there is still work to do. Too many people remain unaware of their risk or lack access to timely screening and treatment. Stigma and fear continue to silence conversations about cervical health. Organizations like Cervivor are helping bridge those gaps by elevating survivor voices, promoting education, and partnering with health systems to ensure innovations reach those who need them most.

Q: What message would you share on this inaugural day?

Tamika: A future without HPV-related cancers looks like prevention in every community, equity in every policy, and hope in every story. It looks like the next generation growing up protected and informed. A world without cervical cancer means no more stories like mine—and that’s the legacy I want to leave behind.

Elimination is possible, but it will take continued investment, accountability, and survivor leadership. Those of us who have lived through cervical cancer know what’s at stake, and we’re committed to making sure no one else has to.

This collage features Cervivor community members from the U.S. and around the world, showcasing powerful patient advocacy and demonstrating what survivor leadership looks like in the fight to eliminate cervical cancer.

Dr. Bagudu: On this inaugural World Cervical Cancer Elimination Day, my message is one of hope and urgency. Hope—because for the first time, we have the tools to end a cancer. Urgency—because every year of delay costs thousands of women’s lives, especially in Africa.

A future without HPV-related cancers is one where girls are routinely vaccinated, women have access to simple, affordable screening close to home, and treatment is available without stigma or financial hardship. It is a future where communities celebrate survivorship rather than mourn preventable loss.

To get there, governments must prioritize vaccination, screening, and treatment; global partners must ensure equitable access; and civil society—including the Medicaid Cancer Foundation—must continue raising awareness, supporting patients, and holding leaders accountable. Innovation, from self-collection for HPV testing to digital health tools, will also be key. 

If you found this blog post helpful, please share it with friends and family. Knowledge is power—and you may just save a life. Questions? Contact us at [email protected].

Cervical Cancer Prevention Starts Here: HPV Vaccine Facts You Can Trust

By Kyle Minnis, Cervivor Communications Assistant

The United States, along with much of the world, is at a pivotal moment in cancer prevention. Various studies show that use of the human papillomavirus (HPV) vaccine—which can prevent over 90% of HPV-related cancers, including cervical cancer—is falling. If the trend continues, more children and families will face potentially life-threatening cancer diagnoses that could be avoided. 

The numbers speak for themselves: According to the Centers for Disease Control’s (CDC) most recent National Immunization Survey, only 78% of U.S. adolescents aged 13 to 17 have received at least one dose of the HPV vaccine, and fewer than 63% are up to date on the full series. This is significantly below the national Healthy People 2030 goal of 80% two-dose completion among adolescents aged 13 to 15. Recent data suggests the pandemic has widened gaps in vaccine uptake and fueled vaccine hesitancy.

Globally, approximately 31% of eligible girls have received at least one dose, though the percentage fully completing the recommended series falls well short of the World Health Organization (WHO) cervical cancer elimination target of 90% completion by age 15. The disease still claims the lives of nearly 400,000 people with a cervix worldwide each year.

As vaccine misinformation floods social media, parents and young adults encounter more conflicting messages than ever. Meanwhile, research infrastructure is under threat. In March 2025, the National Institutes of Health (NIH) terminated all funded research on vaccine hesitancy and uptake, telling scientists: “This award no longer effectuates agency priorities.” 

“Watching the headlines and talking to experts in the field, we know this is a critical time,” says cervical cancer survivor Tamika Felder, Cervivor’s Founder and Chief Visionary and co-chair of the American Cancer Society’s National HPV Vaccination Roundtable. “Respected scientists are being dismissed. Research is being defunded. ‘Vaccine’ has become an even more loaded word. And decades of hard-earned progress are at risk.” 

Cervivor Founder Tamika (center) addresses the audience at the 2025 National HPV Conference, a key gathering for leaders in HPV prevention.

For Cervivor Ambassador Zuli Garcia, who will mark her second cancer-versary this November, the issue is deeply personal. As a 2024 Cervivor School graduate and founder of Knock and Drop Iowa, she advocates for underserved families who often face barriers to timely HPV cancer prevention. “I’m living proof of what happens when access comes too late,” says Zuli, who was diagnosed at age 47. “The HPV vaccine represents hope, protection, and equity.”

To cut through the noise and offer clear, trustworthy HPV vaccine facts during National Immunization Awareness Month (NIAM), we’ve gathered insights from survivors and leading experts. What follows is a breakdown of the most essential information about the HPV vaccine—and why it’s needed to protect future generations from preventable cancers.

Why HPV Vaccination Matters More Than Ever

Every major health authority agrees: The HPV vaccine saves lives from cervical cancer and five other HPV-related cancers—including anal, throat, penile, vaginal, and vulvar cancers. Among teen girls, infections with the HPV types that cause most cancers have dropped by 88%, while infections among young women have dropped by 81%, according to a 2024 CDC report. Additionally, among vaccinated women, cervical precancers caused by high-risk HPV types have declined by 40%, with some studies showing up to 80% reductions in high-grade lesions among those vaccinated early.

In countries like Australia and Sweden—thanks to widespread vaccination and strong screening programs—HPV is close to being eliminated as a cause of cervical cancer. 

Dr. Heather Brandt

Dr. Heather Brandt, director of the HPV Cancer Prevention Program at St. Jude Children’s Research Hospital, stresses both the progress made and the work still ahead. “Here we are after almost 20 years of the vaccination being available and still working to make sure people understand how HPV vaccination protects against these diseases,” she says. She recalls feeling “such excitement” at the 2002 International Papillomavirus Conference when early trial results showed the vaccine could prevent HPV-related diseases, pre-cancers, cancers, genital warts, and even recurrent respiratory papillomatosis.

Today, after more than 15 years and over 500 million doses given worldwide, the vaccine’s safety record remains excellent. Serious side effects are extremely rare, and most reactions are mild, such as temporary soreness or fever. Real-world studies confirm that protection lasts at least 12 years—and likely much longer.

Who Should Get the HPV Vaccine and When?

Everyone—regardless of gender—should get the HPV vaccine. Here are the latest immunization guidelines: 

  • The ideal time to start is between ages 11 and 12, though it can be given as early as age 9 for maximum protection. 
  • If the first dose is given before age 15, only two doses are needed. 
  • For those starting later or who are immunocompromised, a three-dose series is recommended. 
  • Catch-up vaccination is advised through age 26, and adults up to age 45 may still benefit based on individual risk and guidance from their healthcare provider.

The following infographic provides additional information on when and why the vaccine is so important for saving lives from preventable cancers.

While insurance coverage for older teens and adults varies, several states—including Washington D.C., Virginia, Rhode Island, and Hawaii, plus Puerto Rico—have implemented school-entry requirements for the HPV vaccine. These policies significantly boost community-wide protection.

“HPV affects everyone—men and women—and the vaccine is about cancer prevention, not lifestyle choices,” says a spokesperson from Vaccinate Your Family, an organization dedicated to raising awareness about timely immunizations. Its current #FirstDayVax campaign aligns with CDC recommendations to bundle the HPV vaccine with other routine back-to-school shots, like Tdap and meningitis. 

Common HPV Vaccine Myths—and How to Address Them

Across the U.S.—especially in rural and conservative communities—misinformation and stigma are stalling progress. Rising non-medical exemptions, often fueled by online disinformation, threaten decades of gains for all vaccines, not just HPV. Without research and infrastructure support, public health programs are left without the tools they need to respond.

Kellie DeFelice

As Vaccinate Your Family warns: “Parents are increasingly exposed to false vaccine claims online, where algorithms and bots amplify misleading content and make anti-vaccine rhetoric appear as credible as scientific consensus.” 

Even parents who support vaccines can be swayed. Kellie Defelice, a Cervivor Ambassador, shares: “I was very pro-vaccine. But after reading a story online, I hesitated and turned down the HPV vaccine for my daughter. I regretted that decision when I was diagnosed with cervical cancer.” Her hope for fellow moms: “They see that I’m the real face of what HPV does—it isn’t just an STI. I risked my daughter getting a cancer that has destroyed so much for me.”

Other common myths include:

  • “The HPV vaccine is just for girls.” In fact, HPV affects everyone. Anal cancer rates in both men and women have been rising, with new cases increasing by about 2.2% per year over the past decade, according to the American Cancer Society. While men may not get cervical cancer, they can still contract and spread high-risk HPV strains.
  • “The vaccine encourages promiscuity.” Zuli explains that some parents worry the vaccine is a “permission slip for sex.” But as Vaccinate Your Family counters, “Vaccination does not change behavior—it simply protects against cancer-causing infections.”
  • “The vaccine isn’t necessary until kids are sexually active.” In reality, the vaccine works best before HPV exposure, which is why health organizations now recommend it for children as young as 9 years old.

How to Get Back on Track with HPV Vaccination Targets

Survivors and experts are pushing back against misinformation with evidence, stories, and culturally relevant outreach. Zuli says: “As a survivor, I’ll keep raising my voice until every child, every family, and every community has access to this protection.”

A review of nearly 60 studies conducted between 2006 and 2019 found that strong provider recommendations are among the most important—if not the most important—drivers of vaccine uptake, underscoring the need to equip health professionals with confidence and clarity in vaccine conversations.

Community partnerships also make a difference. In Memphis, the St. Jude HPV Cancer Prevention Program helped boost county vaccination rates by 19%, outpacing national averages. In Iowa, Zuli’s team at Knock and Drop Iowa combines bilingual education with on-site vaccinations—reaching 23 people in a single afternoon, she reports. “Meeting people where they are is what works,” Zuli explains. “Education first, vaccines immediately after, in a trusted setting.”

Cervivor Ambassador Zuli Garcia hosts an HPV vaccine outreach event in her home state of Iowa.

Vaccinate Your Family echoes this approach: “Conversations about vaccines should always start with empathy, not judgment. Questions about safety, side effects, or the need for certain vaccines are natural—and families should look to trusted, science-based sources.”

St. Jude’s Dr. Brandt highlights new “compelling” research: “Through our work…we have been discussing the implications of possible changes to the dosing schedule with partners. I know all of us are incredibly excited about the prospect of moving to a single dose in the U.S.”

She also offers caution: “We previously leaned in on the rigor of the FDA-approval processes for childhood vaccinations and then review by the Advisory Committee on Immunization Practices. Key changes to these entities may call into question the science. Changes in dosing with any gaps in evidence become fodder for purveyors of misinformation.”

Ultimately, cancer prevention shouldn’t be controversial—it should be celebrated. By recommitting to science, survivor voices, and trusted outreach, we can ensure every person has the chance to thrive, free from preventable cancers.

If you found this blog post helpful, please share it with friends or family members of recommended vaccination age. You may just save a life. 

About the Author

The image is a portrait of a young man with dark skin and short, curly black hair. He is wearing a blue collared shirt and black-framed glasses, and is smiling at the camera. The man has dark skin and short, curly black hair. His hair is cut close to his head, with a slight fade at the sides. His eyebrows are thick and well-groomed. He is wearing a blue collared shirt. The shirt is a medium blue color and appears to be made of a lightweight material. It has a relaxed fit and is buttoned up to the top. He is also wearing black-framed glasses. The frames are rectangular in shape and have a subtle curve at the temples. The lenses are clear and do not appear to have any tint or coating. The man is smiling at the camera. His smile is wide and genuine, showing off his white teeth. His eyes are crinkled at the corners, giving him a friendly and approachable appearance. The background of the image is a plain gray color. The gray is a medium tone, neither too light nor too dark. It provides a neutral backdrop that allows the subject to stand out. Overall, the image presents a friendly and approachable young man who appears to be confident and comfortable in front of the camera

Kyle Minnis is a senior studying Strategic Communications at the University of Kansas. He is currently serving as Cervivor’s Communications Assistant.